<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940731</url>
  </required_header>
  <id_info>
    <org_study_id>CCTQ01458-2-CTF</org_study_id>
    <nct_id>NCT01940731</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults</brief_title>
  <official_title>A Prospective, Open, Non-controlled, Multi-center Study of Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the clinical and microbiological efficacy and safety of Colistimethate&#xD;
           sodium Injection Vial to treat adults with hospital-acquired pneumonia .&#xD;
&#xD;
        2. To Learn the pharmacokinetic characteristics of continuous intravenous infusion of&#xD;
           Colistimethate sodium.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per subject clinical cure rate</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Per subject microbiological cure rate</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hospital-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Colistimethate sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistimethate sodium</intervention_name>
    <description>3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day</description>
    <arm_group_label>Colistimethate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 18-75, either male or female&#xD;
&#xD;
          2. Women of childbearing age having negative pregnancy test at the time of enrollment and&#xD;
             agreeing to take effective contraceptive measures from the delivery to 7 ~14 days&#xD;
             after stopping .&#xD;
&#xD;
          3. Defined as hospital-acquired pneumonia with following criteria&#xD;
&#xD;
          4. fever, axillary temperature ≥37.3℃, oral temperature≥37.8℃, tympanic&#xD;
             temperature≥38.2℃, rectal temperature≥38.4℃ or hypothermia rectal temperature&lt;35℃&#xD;
&#xD;
          5. WBC&gt;10000/μL or &lt;4000μL, neutrophils&gt;70%, rod neutrophils&gt;10%&#xD;
&#xD;
          6. Pathogens are or highly suspected to be aerobic gram-negative bacilli.&#xD;
&#xD;
          7. Before 72h of admin agents, drug treatment which used for Systemic antibacterial&#xD;
             activity against gram-negative bacteria,is less than 48 hours. If it was more than&#xD;
             48h, there must be evidence for clinic failure, eg. continue fever.WBC and neutrophils&#xD;
             irregular, or respiratory secretions/blood bacterial culture are positive.&#xD;
&#xD;
          8. Informed consent granted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pneumonia infected within 48h admission.&#xD;
&#xD;
          2. Before 72h of admin agents, drug treatment for Systemic antibacterial activity is more&#xD;
             than 48 hours, unless clinical treatment failure .&#xD;
&#xD;
          3. Patients known or suspected by the single infection of aerobic Gram-positive cocci.&#xD;
&#xD;
          4. Patients known to have single or mixed infections by Stenotrophomonas narrow food&#xD;
             Aeromonas or Burkholderia.&#xD;
&#xD;
          5. Patients with impaired consciousness.&#xD;
&#xD;
          6. Patients with primary pulmonary fibrosis, cystic fibrosis, lung cinerea pneumonia,&#xD;
             active tuberculosis, Bronchial obstruction, history of obstructive pneumonia (mild to&#xD;
             severe COPD were admission), primary lung cancer, other tumor metastasis to the lungs,&#xD;
             bronchiectasis, lung abscess, empyema, non-infectious interstitial lung disease,&#xD;
             pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophil infiltration,&#xD;
             pulmonary vasculitis, pleural effusion as the primary foci, aspiration pneumonia,&#xD;
             fungal pneumonia and atypical pathogens pneumonia.&#xD;
&#xD;
          7. Patients have other bacterial infection lesions and require other antimicrobial drug&#xD;
             therapy that may hinder the efficacy of the study drug evaluation.&#xD;
&#xD;
          8. Glucocorticoids（eg ,prednisone 20mg/d, treatment≥2 week） and immunosuppressant were&#xD;
             used，or known HIV positive and immunocompromised.&#xD;
&#xD;
          9. Patients have immediate evidence of life-threatening diseases, including, but not&#xD;
             limited to, acute congestive heart failure, acute coronary syndrome, or unstable&#xD;
             arrhythmia.&#xD;
&#xD;
         10. Patients with sustainable shock after making adequate fluid resuscitation (systolic&#xD;
             blood pressure &gt;90mmHg) for more than 2h and having evidence of hypoperfusion or need&#xD;
             sympathomimetic drugs to keep steady blood pressure.&#xD;
&#xD;
         11. Patients with severe neutropenia syndrome (neutrophils&lt;500 cells/mm3) or expected to&#xD;
             suffer severe reduction in neutrophil within 14days, or had taken G-GSF before 48h of&#xD;
             study.&#xD;
&#xD;
         12. Any patients with end-stage disease.&#xD;
&#xD;
         13. Patients have medical record with multiple polymyxin anaphylactoid reactions.(&#xD;
             urticaria, angioedema, anaphylaxis, rash, scaling, etc.)&#xD;
&#xD;
         14. Patients have Child Pugh C chronic liver disease, or liver function is abnormal.( AST&#xD;
             or AST/ALT were greater than 5 times the upper limit of normal, total bilirubin&#xD;
             greater than 2 times the upper limit of normal)&#xD;
&#xD;
         15. Patients in need of major surgery&#xD;
&#xD;
         16. Patients with moderate or severe renal impairment (CrCL&gt;50ml/min)&#xD;
&#xD;
         17. Patients have taken part in clinical trials of Colistimethate sodium。&#xD;
&#xD;
         18. Patients have taken part in other drug and instrument clinical trials.&#xD;
&#xD;
         19. Pregnant , breastfeeding and keep breastfeeding&#xD;
&#xD;
         20. Patients involving in planning or operation of study&#xD;
&#xD;
         21. Patients have poor compliance with study-specific procedures and related restrictions.&#xD;
&#xD;
         22. disease which may be harmful to patients or quality of data&#xD;
&#xD;
         23. History of epilepsy or myasthenia gravis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu Ju Fang</last_name>
    <phone>13816357099</phone>
    <email>Wujf53@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital ,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Seond Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <zip>13004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth people's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

